EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study

Po-Wei Liao, Hsueh-Ju Lu, Tsung-Chih Chen, Hsin-Chen Lin, Yu-Hsuan Shih, Chieh-Lin Jerry Teng iD

Cancer Reports · 2024

DOI: 10.1002/cnr2.2102 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Reports, 2024. Verfasst von Po-Wei Liao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Multiple Myeloma, Thalidomide, Dexamethasone, Bortezomib. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TTY Biopharm, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thalidomide‐containing regimens cause adverse events (AEs) that may require a reduction in treatment intensity or even treatment discontinuation in patients with multiple myeloma. As thalidomide toxicity is dose‐dependent, identifying the most appropriate dose for each patient is essential.

Aims

This study aimed to investigate the effects of a thalidomide dose step‐up strategy on treatment response and progression‐free survival (PFS). Methods and Results This prospective observational study included 93 patients with newly diagnosed multiple myeloma (NDMM) who received bortezomib, thalidomide, and dexamethasone (VTD). The present study assessed the incidence of thalidomide dose reduction and discontinuation, the overall dose intensity, and their effects on therapeutic efficacy. Furthermore, this study used Cox proportional hazard models to analyze the factors contributing to thalidomide intolerability. The results showed the overall response rates in all patients and the evaluable patients were 78.5% and 98.7%, respectively. The median PFS in the study cohort was not reached. The most common thalidomide‐related AEs were constipation (32.3%) and skin rash (23.7%), resulting in dose reduction and discontinuation rates of 22.6% and 21.5%, respectively. The responders had a significantly higher average thalidomide dose intensity than the nonresponders (88.6% vs. 42.9%, p < .001).

Conclusion

The thalidomide dose step‐up approach is a viable option for patients with NDMM receiving VTD induction therapy with satisfactory efficacy and tolerability. However, thalidomide intolerance may lead to dose reduction or discontinuation due to unpredictable AEs, leading to lower dose intensity and potentially inferior treatment outcomes. In addition to a dose step‐up strategy, optimal supportive care is critical for patients with multiple myeloma receiving VTD induction therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaThalidomideDexamethasoneBortezomibAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleProspective StudiesAgedMiddle AgedAdultInduction ChemotherapyProgression-Free SurvivalAged, 80 and overDose-Response Relationship, Drug

Stichwörter der Autor:innen

adverse eventsconstipationdose intensityoverall survivalprogression‐free survival

Substanzen

ThalidomideDexamethasoneBortezomib

Autor:innen und Institutionen

  • Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
  • Department of Life Science, Tunghai University, Taichung, Taiwan.
  • Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

ORCID-Profile: Chieh-Lin Jerry Teng

Förderung

  • TTY Biopharm, Taiwan

Zitieren

APA

Liao, P. W., Lu, H. J., Chen, T. C., Lin, H. C., Shih, Y. H., & Teng, C. J. (2024). The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study. Cancer Reports. https://doi.org/10.1002/cnr2.2102

Vancouver

Liao PW, Lu HJ, Chen TC, Lin HC, Shih YH, Teng CJ. The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study. Cancer Reports. 2024. doi:10.1002/cnr2.2102

BibTeX
@article{Liao2024,
  author = {Liao, Po-Wei and Lu, Hsueh-Ju and Chen, Tsung-Chih and Lin, Hsin-Chen and Shih, Yu-Hsuan and Teng, Chieh-Lin Jerry},
  title = {The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2102}
}
Kostenlos starten →